Last reviewed · How we verify
insulin degludec/insulin aspart
At a glance
| Generic name | insulin degludec/insulin aspart |
|---|---|
| Also known as | IDegAsp |
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (PHASE2)
- A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) (PHASE3)
- Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes (PHASE3)
- Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM (NA)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin degludec/insulin aspart CI brief — competitive landscape report
- insulin degludec/insulin aspart updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI